New Glu Research Opportunity

We’re partnering with our friends at Tidepool to study how daily highs and lows might affect the health and well-being of people with type 1 diabetes.

Senseonics Pairs its Implantable CGM with Glooko

By Craig Idlebrook/GluCraig

Senseonics has announced today that it has entered into a partnership with Glooko to pair the software company’s platform with its implantable CGM.

Under the agreement, Eversense CGM users will be able to sync their data from the Senseonics cloud directly to Glooko’s blood sugar management platform. This will enable users of the implantable CGM to see their glucose trends on the Glooko app, according to the press release. However, users apparently will not be able to see real-time glucose trends on the app; they will still need to get real-time readings through the Eversense app.

Both Senseonics and Glooko have enjoyed good news cycles recently. In April it was announced that Senseonics was the first to gain FDA approval for an implantable CGM. A few weeks later, Glooko announced it had partnered with DreaMed, an artificial intelligence software company that analyzes glucose trends to suggest changes in insulin management.

Glooko and Senseonics plan for the integration to be complete by the end of the year.

Want more type 1 diabetes-related news stories, and the chance to help type 1 diabetes research? Take a moment to join Glu now by clicking here: https://myglu.org/sign_up.

 

Sign in or Register to view comments.